Vir Bio's Cancer Treatment Progress Driving Shares Hight
March 2, 2026
11 min
Full
5,175 of 5,353
March 2, 2026
Vir Bio's Cancer Treatment Progress Driving Shares Hight
0:00 / 11:13
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Bloomberg Originals Episodes Around March 2, 2026
Episode 5,175 of 5,353 — walk the feed in the order it was published.
11:13This episodeVir Bio's Cancer Treatment Progress Driving Shares Hight
Summary
<p>Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity.<br /><br />Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.